Anzeige
Meldung des Tages: China drosselt, Preise explodieren: Wird dieser kaum bekannte Rohstoff zum nächsten Milliarden-Play?

Jazz Pharmaceuticals News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
180,99 $
-1,22 $
-0,67%
156,89 € 17.03.26
Depot/Watchlist
Marktkapitalisierung *
8,78 Mrd. €
Streubesitz
-
KGV
-
Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,41: JU6CB1
Werbung

Jazz Pharmaceuticals News

02.10.25 - PR Newswire
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-​Line Maintenance Therapy for Extensive-​Stage Small Cell Lung Cancer PR Newswire
22.09.25 - PR Newswire
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-​World ...
09.09.25 - PR Newswire
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
21.08.25 - PR Newswire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 PR Newswire
20.08.25 - PR Newswire
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 PR Newswire
06.08.25 - PR Newswire
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma PR Newswire
05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.08.25 - PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
22.07.25 - PR Newswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
10.07.25 - PR Newswire
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire
01.07.25 - PR Newswire
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR ...
10.06.25 - PR Newswire
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-​Line Maintenance Treatment of Extensive-​Stage Small Cell Lung ...
09.06.25 - PR Newswire
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Jazz Pharmaceuticals Presents Late-​Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-​Line Maintenance Therapy for ...
02.06.25 - PR Newswire
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-​hrii) in First-​Line HER2-Positive Metastatic ...

Newssuche

Videos

newspaper
16.03.26 +1,50%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »